Copyright
©The Author(s) 2016.
World J Gastroenterol. Jul 28, 2016; 22(28): 6345-6361
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6345
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6345
Figure 1 Epidermal growth factor receptor and its downstream signaling pathway.
Binding of ligands such as epidermal growth factor (EGF) to Epidermal growth factor receptor (EGFR) activates downstream Ras/ERK and PI3K/Akt pathways and regulates various physiological processes. The anti-EGFR monoclonal antibodies (mAbs) cetuximab and panitumumab block the activation of these pathways.
- Citation: Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016; 22(28): 6345-6361
- URL: https://www.wjgnet.com/1007-9327/full/v22/i28/6345.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i28.6345